Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson’s disease: a systematic review

Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson’s disease: a systematic review

Objective The aim of this report was to systematically evaluate the efficacy and safety of rasagiline (R) plus levodopa ( l ) (R + l ) for the treatment of Parkinson’s disease (PD) compared with that of l monotherapy, in order to provide a reference resource for rational drug use. Methods Randomized...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurological sciences 2020, Vol.41 (1), p.101-109
Hauptverfasser: Jiang, De-Qi, Wang, Hua-Kun, Wang, Yan, Li, Ming-Xing, Jiang, Li-Lin, Wang, Yong
Format: Artikel
Sprache:eng
Schlagworte:
Activities of daily living
Clinical trials
Levodopa
Medicine
Medicine & Public Health
Movement disorders
Neurodegenerative diseases
Neurology
Neuroradiology
Neurosciences
Neurosurgery
Original Article
Parkinson's disease
Psychiatry
Rasagiline
Sensitivity analysis
Systematic review
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective The aim of this report was to systematically evaluate the efficacy and safety of rasagiline (R) plus levodopa ( l ) (R + l ) for the treatment of Parkinson’s disease (PD) compared with that of l monotherapy, in order to provide a reference resource for rational drug use. Methods Randomized controlled trials (RCTs) of R + l for PD published up to September 2018 were searched. Sensitivity analyses were also performed. Results Fourteen RCTs with 2531 participants were included. Compared with l monotherapy, the pooled effects of R + l combination therapy on unified Parkinson’s disease rating scale (UPDRS) score were (SMD − 0.50, 95% CI − 0.70 to − 0.30, P  
ISSN:1590-1874
1590-3478
DOI:10.1007/s10072-019-04050-8